Collectively, our data demonstrate that the PRAME-targeting ImmTAC® can redirect T cells to selectively and efficiently kill PRAME+/HLA-A*02:01+ tumor cells with varying levels of PRAME expression and peptide presentation. Here, HLA-A is linked to neoplasm.